CCO Official Conference Coverage
|
|
XVIII International AIDS Conference (AIDS 2010)*
July 18-23, 2010 | Vienna, Austria
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Mouse over track for more info
|
CCO Slideset
Highlights of AIDS 2010
 |
|
Joseph J. Eron, Jr., MD, and Joel E. Gallant, MD, MPH, review the most clinically relevant data from this important conference.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.93 MB
| Date posted: 8/5/2010
|
Expert Highlights
 |
Diane V. Havlir, MD, scientific committee co-chair of AIDS 2010, welcomes us to Vienna and previews some of the most important scientific data that will be introduced at the meeting. (7 minutes) |
 |
Download Audio |
 |
Jürgen K. Rockstroh, MD, reviews the oral and poster session on hepatitis coinfection from AIDS 2010. (7 minutes) |
|
Download Audio |
 |
Pablo Tebas, MD, reviews selected presentations on metabolic complications and discusses the posters on Vitamin D deficiency. (6 minutes) |
|
Download Audio |
 |
Elly Katabira, MD, the incoming President of the International AIDS Society, provides a wrap-up of the meeting focusing on data from resource-limited settings. (4 minutes) |
|
Download Audio |
Conference News – Reported by NAM
|
|
|
|
Click here for more news reports and to learn more about NAM. | |
Conference Webcasts – From the Kaiser Family Foundation
|
|
|
 |
Click here for all available IAC Webcasts from the Kaiser Family Foundation. | |
Partnership Information
|
|
|
|
AIDS 2010 conference organizers are using a blog and other social media to communicate with delegates attending the meeting and with those following the conference from home.
AIDS 2010 Blog
Read the AIDS 2010 Blog for posts from conference organizers and guest bloggers.
Social Media
AIDS 2010 updates are available at Facebook, Twitter, YouTube, and Flickr.
For more information about these resources and AIDS 2010, go to www.aids2010.org.
|
| The Kaiser Family Foundation, an independent operating foundation and non-partisan source of information, facts, and analysis, is the official Webcaster of AIDS 2010. In addition to more than 50 online Webcasts of conference sessions, Podcasts will be available in both English and Russian. Some sessions, including the opening and closing ceremonies, will be presented via live Webcast, whereas other coverage will be tape-delayed by a few hours and available on-demand. A daily video recap of the conference developments with Science magazine’s Jon Cohen will also be available. A guide to the daily coverage is available at www.kff.org/aids2010. |
|
www.aidsmap.com provides comprehensive news coverage of AIDS 2010, with news reports each day and a daily summary email bulletin for those who want just the highlights of the meeting.
To view the daily news coverage, and to sign up for the daily highlights bulletin (also available in French, Spanish, Portuguese and Russian) go to www.aidsmap.com/vienna2010.
|
|
Disclosures – Audio Expert Highlights
Diane V. Havlir, MD, has disclosed that she is an investigator on a NIH-sponsored study for which Abbott Laboratories supplies study medication.
Jürgen K. Rockstroh, MD, has disclosed that he has received grants for research support from Abbott Laboratories, Merck, and Roche. He has served as a consultant and has served on an advisory board or panel for Abbott Laboratories, Bionor, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Roche, Tibotec and Viiv.
Pablo Tebas, MD, has disclosed that he has financial relationships with Merck, Pfizer, and Tibotec Therapeutics.
Elly Katabira, MD, has no significant financial relationships to disclose.
|
Jointly sponsored by USF Health and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
PROGRESS: Lopinavir/Ritonavir + Raltegravir Efficacy Noninferior to Lopinavir/Ritonavir + NRTIs in Treatment-Naive Patients at Week 48
Similar proportions of patients with HIV-1 RNA < 40 copies/mL at Week 48 in both treatment arms, with similar adverse event profiles, although some lipid parameters significantly higher in lopinavir/ritonavir + raltegravir arm.
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|